Skip to main content

Table 2 Erase Hep C study SPIRIT figure

From: Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study — a prospective single-arm intervention trial

 

Screen

Enrollment

Treatment

Start

End (Glecaprevir / Pibrentasvir)

End (Sofosbuvir / Velpatasvir)

SVR12 (Glecaprevir / Pibrentasvir)

SVR12 (Sofosburvir / Velpatasvir)

Timepoint

T-1

T0

T1 = up to 90 days after T0

T2 = T1 + 60 days

T3 = T1 + 90 days

T4 = T2 + (90–120 days)

T5 = T3 + (90–120 days)

ENROLLMENT:

 Eligibility Screen

X

      

 Informed Consent

 

X

     

 Interview

 

X

 

X

X

  

 Obtain EMR Data

X

X

X

X

X

X

X

INTERVENTION:

 Implement Site-Specific HCV Treatment Workflows

 

X

X

X

X

X

X

ASSESSMENTS:

 Demographic Variables

 

X

 

X

X

  

 Socioeconomic Variables

 

X

 

X

X

  

 Substance Use Variables

 

X

 

X

X

  

 Sexual Behavior Variables

   

X

X

  

 Medical History

 

X

 

X

X

  

 Labs

X

X

 

X

X

  

 SVR12

     

X

X

 2º Clinical Outcomes

  

X

X

X

X

X

 2º Implementation Outcomes

  

X

X

X

X

X

Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784